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Sprifermin (rhFGF18) modulates 
extracellular matrix turnover in cartilage 
explants ex vivo
Ditte Reker1,3*, Cecilie F. Kjelgaard‑Petersen1,4, Anne Sofie Siebuhr1, Martin Michaelis2, Anne Gigout2, 
Morten A. Karsdal1, Christoph Ladel2 and Anne C. Bay‑Jensen1*
Abstract 
Background: Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential 
disease‑modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of 
sprifermin involve chondrocyte proliferation and extracellular matrix (ECM) production. To gain further insight into the 
process of sprifermin in the cartilage tissue, this study aimed at investigating the ECM turnover of articular cartilage 
explants in a longitudinal manner.
Methods: Bovine full‑depth articular cartilage explants were stimulated with sprifermin or placebo at weekly inter‑
vals, similar to the dosing regimen used in clinical trials. Pre‑culturing with oncostatin M and tumour necrosis factor‑α, 
was also used to induce an inflammatory state before treatment. Metabolic activity was measured using AlamarBlue, 
and chondrocyte proliferation was visualized by immuno‑histochemical detection of proliferating cell nuclear anti‑
gen. ECM turnover was quantified by biomarker ELISAs; ProC2 reflecting type II collagen formation, CS846 reflecting 
aggrecan formation, active MMP9, C2M and AGNx2 reflecting matrix metalloproteinase activity, and AGNx1 reflecting 
aggrecanase activity.
Results: Sprifermin was able to reach the chondrocytes through the extracellular matrix, as it increased cell prolifera‑
tion and metabolic activity of explants. ProC2 and CS846 was dose‑dependently increased (P < 0.05) by sprifermin 
compared to placebo, while C2M and AGNx2 were unaffected, active MMP9 was slightly decreased, and AGNx1 was 
slightly increased. Over the course of treatment, the temporal order of ECM turnover responses was AGNx1, then 
ProC2, followed by CS846 and MMP9. Pro‑inflammatory activation of the explants diminished the ECM turnover 
responses otherwise observed under non‑inflammatory conditions.
Conclusions: The data suggest that sprifermin has chondrogenic effects on articular cartilage ex vivo, exerted 
through a sequential process of ECM turnover; aggrecan degradation seems to occur first, while type II collagen and 
aggrecan production increased at a later time point. In addition, it was observed that these chondrogenic effects are 
dependent on the inflammatory status of the cartilage prior to treatment.
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Background
Osteoarthritis (OA) is in urgent need of novel therapies 
that are not limited to alleviating symptoms, but rather 
have the ability to interfere with disease progression. 
As such, disease-modifying OA drugs (DMOADs) may 
target any of the joint tissues involved in OA, either by 
inhibiting the degenerative processes or by inducing 
regeneration. Sprifermin (recombinant human fibro-
blast growth factor 18, rhFGF18), is a novel DMOAD 
candidate that specifically targets articular cartilage and 
induces its regeneration.
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The cartilage regenerative properties of sprifermin have 
been confirmed in vivo, by delivering sprifermin directly 
to the joint cavity as intraarticular injections once weekly. 
Animal studies have shown that intraarticular sprifer-
min prevent cartilage degradation and stimulate repair 
of damaged cartilage in traumatic OA models [1, 2], 
and has the ability to improve cartilage repair following 
micro-fracture treatment of chondral defects in an ovine 
model [3]. A first-in-man study in OA patients scheduled 
for knee joint replacement, delivered first indications that 
intraarticular sprifermin may have anabolic effects on 
joint cartilage by stimulating chondrocyte proliferation 
and positively influencing histological and biomechani-
cal properties [4]. Later, in a phase Ib clinical study of 
intraarticular sprifermin, the primary end point, reduc-
tion of cartilage loss in the central medial femorotibial 
compartment, was not met. However, the secondary end 
points were consistent with a dose-related treatment 
effect on the cartilage across the total femorotibial joint 
and in the lateral femorotibial compartment [5]. Lastly, 
2-year primary data from the currently ongoing 5-year 
phase II study was presented at this year’s American Col-
lege of Rheumatology (ACR) Annual Meeting, showing a 
dose-dependent increase in total femorotibial joint car-
tilage thickness [6]. Thereby, the primary end point was 
met. No local or systemic serious safety concerns have 
been reported with intraarticular sprifermin [4–6].
In vitro studies have shown that sprifermin mainly acti-
vates the FGF receptor 3 (FGFR3) on the surface of the 
chondrocytes [7, 8]. By signalling through this receptor 
sprifermin induces cell proliferation [1, 2, 8–10] and for-
mation of extracellular matrix (ECM) molecules; type II 
collagen [3, 7–10] and aggrecan [7–11], while promoting 
the chondrocyte phenotype [9, 10]. Together these results 
indicate that sprifermin induces cartilage formation 
by increasing the chondrocyte population and thereby 
allow increased ECM production. We have recently pub-
lished data showing this effect in response to once weekly 
administration of sprifermin [10]. However, with perma-
nent administration of sprifermin, cell proliferation was 
strongly stimulated at the expense of matrix production 
[10]. This indicates that the process of cartilage regenera-
tion is a delicate balance between cellular and extracel-
lular changes.
With the present study, we aimed at investigating the 
temporal changes in ECM turnover of articular cartilage 
explants in response to sprifermin, to gain insight into 
the longitudinal processes induced in the cartilage tis-
sue. To do this, ex vivo articular cartilage explants were 
stimulated with sprifermin or placebo at weekly intervals 
to mimic the weekly intraarticular injections used in the 
clinic. The first aim was to confirm that anabolic effects 
previously observed in  vitro [1–3, 7–11] could also be 
detected in explants, i.e. whether the chondrocytes could 
be reached through the matrix, and if chondrocytes in 
their physiological environment respond similarly than 
in cell culture. This was done by monitoring cell prolif-
eration, metabolic activity and ECM formation (ProC2). 
Next, we speculated that chondrocyte proliferation may 
be accompanied by some degree of ECM degradation to 
expand the lacunae, and that ECM turnover (both for-
mation and potential degradation) may be a function 
of time of treatment. Therefore, the second aim was to 
investigate the anabolic effects and potential catabolic 
effects over time, by monitoring ECM turnover biomark-
ers (ProC2, CS846, C2M, AGNx2, active MMP9 and 
AGNx1). Lastly, we speculated that the cartilage regen-
erative effects observed in vivo may be influenced by the 
inflammatory status of the joint cavity. Hence, the third 
aim was to investigate the influence of pro-inflammatory 
cytokines, oncostatin M (OSM) and tumor necrosis fac-
tor alpha (TNF-α), on sprifermin-induced ECM turnover 
(ProC2, C2M, AGNx2 and AGNx1).
Methods
Bovine full‑depth articular cartilage explant culture
To investigate how both cellular and extracellular com-
ponents of articular cartilage were affected by sprifermin 
compared to placebo, the well-described bovine full-
depth articular cartilage explant model was used [12–18]. 
The effect parameters were tested on articular carti-
lage retrieved from three cows to account for biological 
variance.
Reagents
The culture medium was composed of DMEM/Nutrient 
Mixture F-12 with GlutaMAX (DMEM/F12-GlutaMAX) 
with 1% Penicillin Streptomycin (PS) both obtained from 
Life Technologies. Phosphate buffered saline (PBS), human 
OSM and human insulin-like growth factor-I (IGF-I) were 
obtained from Sigma-Aldrich, and human TNF-α were 
from R&D systems. The sprifermin used was drug prod-
uct formulated for intra-articular administration obtained 
from Merck-Serono together with the corresponding pla-
cebo formulation. The placebo formulation contained 
7 mM  Na2HPO4, 1.0 mM  KH2PO4, 2.7 mM KCl (pH 7.3).
Tissue preparation
Full-depth articular cartilage explants were harvested 
from the femoral condyle of the hind leg of cows 
aged ≤  2  years, retrieved from the local slaughterhouse 
maximum 2  days after slaughtering (Harald Hansen). A 
biopsy punch with a 3 mm diameter (Miltex) was used to 
isolate full-depth cartilage plugs (i.e. explants) extending 
from the superficial layer to the subchondral bone. The 
isolated explants (10–20  mg, 2–3  mm in height) were 
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randomly distributed in 96-well culture plates, washed 
three times in sterile PBS and cultured in DMEM/
F12-GlutaMAX with 1% PS at 37 °C, 5%  CO2.
Study design
Three studies were performed and reported indepen-
dently using cartilage explants retrieved from three inde-
pendent cows, one cow per study. In Study 1, the explants 
were cultured for 3 weeks with stimulation by sprifermin 
(900  ng/mL) or placebo in one media change per week 
(72  h duration). Twelve replicate explants were included 
for each condition and three of these were isolated for 
immuno-histochemical analysis after 1, 2 and 3 weeks. In 
Study 2 and 3, the explants were pre-cultured for 1 week 
either without stimulation or with continuous stimulation 
by the cytokines OSM (5 ng/mL) and TNF-α (10 ng/mL) 
(OSM + TNF-α). The pre-culturing period was followed 
by a compound-culturing period of 5 weeks with stimu-
lation by the following compounds in one media change 
per week (48  h duration: sprifermin (1, 10, 50, 100 and 
500 ng/mL) or placebo in Study 2 and sprifermin (11, 33, 
100, 300 and 900 ng/mL) or placebo in Study 3. Six repli-
cate explants, distributed diagonally in the culture plate, 
were included for each condition. Control groups receiv-
ing IGF-I (100  ng/mL) as positive control for cartilage 
formation (ProC2) were included in all studies. Generally, 
the conditioned media were collected three times weekly 
and stored at −  20  °C for further analyses. At the same 
time, freshly prepared medium was added either with 
(once a week) or without (remaining days) compounds.
Metabolic activity and cell proliferation
AlamarBlue assay
AlamarBlue reagent (Life Technologies) was used as a 
non-toxic reagent for quantifying the metabolic activity 
of the explants at termination of each study and peri-
odically during culturing. Briefly, conditioned media 
were collected and 200  μL 10% AlamarBlue in culture 
medium was added to each well with explants and four 
empty control wells. After 3  h. of incubation at 37  °C, 
5%  CO2, 160  μL of the oxidized liquid was transferred 
to black microtiter plates and the fluorescence was read 
at 540 nm excitation and 590 nm emission wavelengths. 
The remaining 40  μL was discarded and the explants 
were washed three times in sterile PBS before fresh cul-
ture medium was added. The readout was corrected for 
background by subtracting the average of the four con-
trols from the result of each explant.
Immuno‑histochemical detection of proliferating cell nuclear 
antigen (PCNA)
Immuno-histochemical detection of PCNA was 
used to visualize cell proliferation in formalin-fixed 
paraffin-embedded (FFPE) tissue slides of explants. 
Briefly, isolated explants were fixed in 4% formalde-
hyde (Merck Millipore) for 2 h at RT, embedded in par-
affin and cut in 5  μm sections. Sections went trough 
de-paraffination, antigen retrieval and blocking, before 
PCNA was bound by anti-PCNA monoclonal mouse 
antibodies (Dako) and visualized by Envision+/HRP 
anti-mouse antibodies (Dako) and DAB+ substrate-chro-
mogen solution (Dako). Sections were then dehydrated 
and mounted. Sections incubated with monoclonal 
mouse IgG2a antibodies (Dako) or PBS as substitute for 
anti-PCNA antibodies were included as negative controls 
for unspecific binding.
Biochemical markers of ECM turnover
ProC2 ELISA
The ProC2 ELISA (Nordic Bioscience) was used to quan-
tify type II collagen formation [13]. The ProC2 competi-
tive ELISA detects the PIIBNP propeptide (QDVRQPG) 
released during trimming of newly synthesized type II 
collagen by N-propeptidases in the ECM. Briefly the 
assay was prepared as following, a streptavidin-coated 
plate was coated with Biotin-QDVRQPG. Samples were 
added together with supernatant from the clone NB443-
3-2-1, producing monoclonal antibodies recognizing the 
PIIBNP propeptide (QDVRQPG). EnVision (Dako), con-
taining peroxidase-conjugated anti-mouse antibodies, 
was used as a detector. 3,3′-5,5′-tetramethylbenzidine 
(TMB) was used as substrate and standard stop solution 
(0.1 M  H2SO4) was added. The colorimetric reaction was 
measured at 450 nm with reference at 650 nm on a stand-
ard laboratory plate reader.
Cs846 ELISA
The CS648 ELISA (IBEX Pharmaceuticals Inc.) was used 
to quantify aggrecan formation. The CS846 competitive 
ELISA detects the CS846 epitope on chondroitin sulphate 
chains of large fetal-like aggrecan [19]. This form of aggre-
can is thought to be synthesized in adult cartilage during 
cartilage repair [20, 21], but needs to be released from 
cartilage by MMP and/or aggrecan cleavage, in order to 
be detected. Briefly the assay was prepared as following, 
a goat anti-mouse antibody-coated plate was coated with 
mouse CS846 antibody. Samples were added together 
with Biotin-CS846. Peroxidase-labelled Streptavidin was 
used as a detector. TMB was used as substrate and stand-
ard stop solution was added. The colorimetric reaction 
was measured at 450 nm with reference at 650 nm on a 
standard laboratory plate reader.
C2M ELISA
The C2M ELISA (Nordic Bioscience) was used to quan-
tify matrix metalloproteinase (MMP)-mediated type II 
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collagen degradation [14]. The C2M competitive ELISA 
detects the C-terminal peptide  (KPPGRDGAAG1053) 
generated by MMP cleavage. Briefly the assay was pre-
pared as following, a streptavidin-coated plate was 
coated with Biotin-KPPGRDGAAG. Samples were added 
together with the peroxidase-labelled monoclonal anti-
body NBCH001, recognizing the C-terminal peptide 
 (KPPGRDGAAG1053). TMB was used as substrate and 
standard stop solution was added. The colorimetric reac-
tion was measured at 450 nm with reference at 650 nm 
on a standard laboratory plate reader.
AGNx1 ELISA
The AGNx1 ELISA (Nordic Bioscience) was used to 
quantify aggrecanase-mediated aggrecan degradation 
[15]. The AGNx1 competitive ELISA detects the C-termi-
nal peptide  (NITEGE373) generated by aggrecanase cleav-
age. This biomarker recognizes all cleavage fragments 
with an exposed NITEGE epitope, thus this includes the 
32  mer (described by Lees et  al. [22]), fragments with 
the G1 domain and even larger fragments with hyalu-
ronic acid still linked to the G1 domain. Briefly the assay 
was prepared as following, a streptavidin-coated plate 
was coated with Biotin-NITEGE. Samples were added 
together with the monoclonal antibody 1H11, recog-
nizing the C-terminal peptide  (NITEGE373). A goat 
anti-mouse antibody was used as a peroxidase-labelled 
detector. TMB was used as substrate and standard stop 
solution was added. The colorimetric reaction was meas-
ured at 450 nm with reference at 650 nm on a standard 
laboratory plate reader.
AGNx2 ELISA
The AGNx2 ELISA (Nordic Bioscience) was used to 
quantify MMP-mediated aggrecan degradation [16, 17]. 
The AGNx2 ELISA detects the fragment 342FFGVG-G2 
by combining two monoclonal antibodies in a sandwich 
ELISA. Briefly the assay was prepared as following, the 
monoclonal antibody AF-28, recognizing the N-termi-
nal neo-epitope (342FFGVG) generated by MMP cleav-
age of the sequence  DIPEN341–342FFGVG, was used as a 
biotinylated catcher. Samples were added, and then the 
monoclonal antibody F78, recognizing the G2 domains 
of aggrecan, was used as a peroxidase-labelled detector. 
TMB was used as substrate and standard stop solution 
was added. The colorimetric reaction was measured at 
450 nm with reference at 650 nm on a standard labora-
tory plate reader.
Active MMP9 ELISA
The active MMP9 competitive ELISA (Nordic Biosci-
ence) detects the N-terminal fragment (FQTFEGDLKW) 
of proteolytically activated MMP9 (unpublished). Briefly 
the assay was prepared as following, a streptavidin-
coated plate was coated with Biotin-FQTFEGDLKW. 
Samples were added together with a peroxidase-labelled 
monoclonal antibody, recognizing the N-terminal frag-
ment (FQTFEGDLKW). TMB was used as substrate and 
standard stop solution was added. The colorimetric reac-
tion was measured at 450 nm with reference at 650 nm 
on a standard laboratory plate reader.
Statistics
Baseline-correction was performed individually for each 
explant by dividing the value at each time point by the 
baseline value (week 0). Placebo-correction was per-
formed individually for each explant by dividing the value 
at each time point by the corresponding mean value 
(n  =  6) of the placebo-treated group. Incremental area 
under the curve (iAUC) was calculated individually for 
each explant using the trapezoidal rule. Values reported 
were mean and standard error of the mean (SEM) of six 
replicate explants (n = 6) originating from one cow. All 
explants in a single study originated from one cow. Sta-
tistical comparisons were only performed within each 
study and therefore between explants from the same cow. 
Unpaired t-test were used for comparison of two treat-
ment groups and one-way ANOVA was used for multiple 
comparisons to the placebo group by assuming normal 
distribution. Statistical tests were performed in Graph-
Pad Prism 6.0. Significance levels are indicated by aster-
isks; *P < 0.05, **P < 0.01, ***P < 0.001.
Results
Sprifermin increases chondrocyte proliferation, metabolic 
activity and ECM formation in cartilage explants
To evaluate the anabolic effect of sprifermin on both the 
cellular and extracellular component of cartilage, cell 
proliferation, metabolic activity and formation of type II 
collagen were monitored in parallel in cartilage explants 
after 0, 1, 2 and 3 weeks of compound-culturing (Study 
1).
Cell proliferation was detected by immuno-histochemi-
cal staining for PCNA, which is an essential protein for 
DNA-replication during cell proliferation. The presence 
of PCNA in chondrocytes was observed in explants iso-
lated after 1, 2 and 3 weeks of culturing with sprifermin 
(900  ng/mL) stimulation once weekly, whereas almost 
none was observed in response to placebo (Fig. 1a). The 
same pattern was observed in 3 replicate explants for 
each time point and treatment. In parallel, metabolic 
activity of the same explants was continuously increased 
by sprifermin compared to placebo after 1, 2 and 3 weeks, 
when correcting for baseline-variance at day 0. After the 
third stimulation, the increase reached statistical signifi-
cance (P  =  0.009, Fig.  1b). To monitor the concurrent 
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Fig. 1 Cell proliferation, metabolic activity and type II collagen formation. Bovine cartilage explants were cultured for 3 weeks with weekly admin‑
istration (72 h duration) of indicated compounds. a Cell proliferation was visualized by staining for PCNA in FFPE tissue slides from three replicate 
explants for each time point and treatment. One representative explant is shown. Scale bar applies to all pictures. b Metabolic activity was meas‑
ured using AlamarBlue after 0, 1, 2 and 3 weeks of compound‑culturing. Values were baseline‑corrected and data presented as mean ± SEM of six 
replicate explants. c ProC2 (Nordic Bioscience) was measured in conditioned media collected at 0, 1, 2 and 3 weeks of compound‑culturing. Values 
were placebo‑corrected and data presented as mean ± SEM of six replicate explants. All results are from one study (Study 1). Unpaired t‑test was 
used to compare the treatment group to the placebo group at each time point. Significance levels are indicated by asterisks; *P < 0.05, **P < 0.01, 
***P < 0.001
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formation of type II collagen by the explants, the bio-
marker ProC2 was quantified in conditioned media har-
vested from these. IGF-I was the positive control of the 
ProC2 assay and IGF-I significantly increased ProC2 at 
all time points (P  <  0.01) compared to placebo. ProC2 
was significantly increased by sprifermin compared to 
placebo (P = 0.041, Fig. 1c), but only after the third stim-
ulation. Hence, while cell proliferation and metabolic 
activity were affected already at the first stimulation by 
sprifermin, ProC2 release was observed at a later stage.
Sprifermin modulates ECM turnover in cartilage explants 
over the course of treatment
To evaluate the temporal effect of sprifermin on ECM 
turnover in cartilage explants, the biomarkers ProC2, 
CS846, C2M, AGNx2, active MMP9 and AGNx1 were 
quantified in the conditioned media harvested from 
explants after 0, 1, 2, 3, 4 and 5 weeks of compound-cul-
turing following pre-culturing in simple culture medium 
(Study 2 and 3).
First, the metabolic activity, quantified at termination of 
each study, was within the normal range for all explants, 
indicating sustained viability throughout the entire cul-
turing period (Fig.  2a). Sprifermin dose-dependently 
increased metabolic activity compared to placebo, reach-
ing statistical significance in both studies (500  ng/mL, 
P = 0.002; 300 ng/mL, P = 0.012).
ProC2, reflecting formation of type II collagen, was 
dose-dependently increased by sprifermin compared to 
placebo (Fig.  2b). The response reached statistical sig-
nificance for the two highest doses at several time points 
(500 ng/mL, P ≤ 0.022; 900 ng/mL, P ≤ 0.022) compared 
to the placebo control. The peak effect of the highest dose 
in study 2 and 3 was observed after the third stimula-
tion by sprifermin, being 5.2-fold higher than placebo in 
Study 2 and 3.7-fold higher in Study 3, when comparing 
mean values. The aggrecan formation biomarker, CS846, 
was dose-dependently increased by sprifermin compared 
to placebo (only evaluated in study 2) (Additional file 1). 
The peak effect of the highest dose was observed after 
the fifth stimulation, being 5.3-fold higher than placebo 
(P = 0.0002).
The catabolic biomarkers C2M and AGNx2, reflect-
ing MMP-mediated degradation of type II collagen and 
aggrecan, respectively, were not affected by any of the 
investigated doses of sprifermin (Fig.  2c, d). Moreo-
ver, active MMP9 was slightly decreased by sprifermin 
compared to placebo, reaching a maximum of 0.6-fold 
decrease after the fifth stimulation by sprifermin (only 
evaluated in study 2) (Additional file 2). In contrast, the 
biomarker AGNx1, reflecting aggrecanase-mediated deg-
radation of aggrecan, was increased by sprifermin com-
pared to placebo (Fig. 2e). The peak effect was observed 
after the first or second stimulation by sprifermin, hence 
at an earlier stage than the ProC2 release described 
above. After the second sprifermin stimulation, the 
mean value of the 100  ng/mL dose was 2.9-fold higher 
than placebo mean value in Study 2 and 2.7-fold higher 
(P = 0.001) in Study 3.
These placebo-corrected comparisons at each specific 
time point (weeks 1–5) are not corrected for the variation 
at baseline (week 0), but the sprifermin-induction clearly 
exceeds baseline-variation. To address the baseline-varia-
tion, a baseline-corrected dataset, comparing the baseline 
level with the following weeks for each treatment group, 
is presented in additional material (Additional file 3).
Pro‑inflammatory pre‑culturing changes the pattern 
of sprifermin‑induced ECM turnover
To evaluate whether the inflammatory status of the car-
tilage explants affected the sprifermin-induced temporal 
changes of ECM turnover, cartilage explants were pre-
cultured with OSM and TNF-α for 1 week prior to com-
pound-culturing in parallel with the explants described 
above (only study 2). The biomarkers ProC2, C2M, 
AGNx2 and AGNx1 were quantified in the conditioned 
media harvested from the explants after 0, 1, 2, 3, 4 and 
5  weeks of compound-culturing. Due to limitations in 
sample volume, AGNx2 could not be quantified at week 
0.
First, the metabolic activity, quantified at termination of 
the study, was within the normal range for all explants, 
indicating sustained viability throughout the entire cul-
turing period (Fig.  3a). As seen with non-inflammatory 
pre-culturing, sprifermin dose-dependently increased 
metabolic activity compared to placebo, reaching statisti-
cal significance for the three highest doses (500  ng/mL, 
P = 0.0003; 100 ng/mL, P = 0.013, 50 ng/mL, P = 0.004).
(See figure on next page.) 
Fig. 2 Metabolic activity and ECM turnover in bovine cartilage explants. Bovine cartilage explants were pre‑cultured for 1 week, and then cultured 
for further 5 weeks with weekly administration (48 h duration) of indicated compounds. Metabolic activity (a) was measured using AlamarBlue after 
5 weeks of compound‑culturing. ProC2 (b), C2M (c), AGNx2 (d) and AGNx1 (e) (Nordic Bioscience) was measured in conditioned media collected at 
0, 1, 2, 3, 4 and 5 weeks of compound‑culturing. Values of biomarkers were placebo‑corrected and all data presented as mean ± SEM of six replicate 
explants. One‑way ANOVA was used for multiple comparisons to the placebo group at each time point. Significance levels are indicated by aster‑
isks; *P < 0.05, **P < 0.01, ***P < 0.001. Results from two studies are shown in separate graphs (Left, Study 2; Right, Study 3)
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Generally, the pro-inflammatory pre-culturing dimin-
ished the patterns of ECM turnover that were observed 
with once weekly stimulation by sprifermin. ProC2 
showed a delayed response after the fourth stimulation 
by sprifermin (500  ng/mL) in OSM  +  TNF-α pre-cul-
tured explants (P  =  0.002), the mean value being 3.1-
fold higher than the placebo mean value (Fig.  3b, left). 
The impact of OSM  +  TNF-α pre-culturing on ProC2 
release was confirmed by directly comparing the iAUC 
of the highest dose for the two pre-culturing conditions, 
showing a statistically significant difference (P =  0.043) 
(Fig. 3b, right). C2M showed an inverse dose-dependent 
increase after the first and second stimulation by sprifer-
min in OSM + TNF-α pre-cultured explants, the maxi-
mum mean value of sprifermin (50 ng/mL) being 2.5-fold 
higher than the placebo mean value (Fig.  3c, left). By 
comparing the iAUC of sprifermin (50  ng/mL) for the 
two pre-culturing conditions, C2M release was slightly 
higher following OSM  +  TNF-α pre-culturing, though 
not statistically significant (Fig.  3c, right). AGNx2 was 
not affected by any of the investigated doses of sprifermin 
(Fig. 3d, left), which was also evident from the iAUC of 
sprifermin (50  ng/mL) for the two pre-culturing condi-
tions (Fig.  3c, right). Lastly, sprifermin did not increase 
AGNx1 in OSM + TNF-α pre-cultured explants (Fig. 3e, 
left), as it did in explants pre-cultured in simple cul-
ture medium (Fig.  2e, left). This difference in response 
between the two pre-culturing conditions is evident from 
the iAUC of sprifermin (100 ng/mL) (Fig. 3e, right).
Discussion
The data of the present study confirm anabolic effects of 
sprifermin previously observed in  vitro [1–3, 7–11], i.e. 
cell proliferation, metabolic activity and ECM formation, 
but here demonstrated in ex  vivo explant cultures. This 
indicates that sprifermin is able to (1) diffuse through the 
ECM to reach the chondrocytes and (2) activate a cel-
lular response from chondrocytes in their physiological 
environment. To summarize, articular cartilage explants 
stimulated with sprifermin at weekly intervals had 
increased cell proliferation, increased metabolic activity, 
and increased formation of type II collagen and aggrecan. 
The last three may be due to increased activity of each 
cell, or simply a result of the expanding cell population, 
or a combination of both.
We think that the observed anabolic effects in the pre-
sent study are likely to be similar to the events occurring 
in sprifermin-treated OA patients. The dose levels used 
are physiologically relevant and the dose regimen is simi-
lar to the one used in the clinic. In the phase II clinical 
trial, OA patients received two or four cycles of treat-
ment 6 or 12 months apart, each consisting of three once 
weekly intraarticular injections of 30–100 μg sprifermin 
or placebo, and the results so far show a dose-depend-
ent increase in total femorotibial joint cartilage thick-
ness [6]. Together these clinical results and our ex  vivo 
results indicate that sprifermin, when delivered directly 
to the joint cavity by intraarticular injections, induces an 
increase in cartilage volume, which is due to first chon-
drocyte proliferation and later type II collagen and aggre-
can formation.
When evaluating the catabolic effects of sprifermin in 
this study, an increase of aggrecanase-mediated aggrecan 
degradation (AGNx1) was found, while MMP-mediated 
degradation was unchanged. Because sprifermin has 
been demonstrated to be an anabolic factor in several 
models in vitro or in vivo, this finding was unexpected. 
However, the lack of MMP-mediated aggrecan degrada-
tion may be attributed to the method used, and it could 
further be hypothesized that this aggrecanase-mediated 
aggrecan degradation occurs to enable chondrocyte pro-
liferation. From ex vivo studies of cartilage degradation 
it is known that aggrecanases and MMPs act indepen-
dently in the processing of aggrecan molecules. During 
cartilage degradation aggrecanase-mediated aggrecan 
degradation occurs in the initial phase, whereas MMP-
mediated aggrecan degradation occurs at a later stage 
[15, 16]. Furthermore, the aggrecan loss occurring in 
the initial phase is completely reversible by IGF-I, while 
the aggrecan loss occurring at a later stage is irrevers-
ible [18]. Therefore, the aggrecanase-mediated aggrecan 
degradation should not be considered simply as an end-
stage degradation process. When aggrecanase-mediated 
aggrecan degradation appears in context of a cartilage 
anabolic process, it may even be speculated that aggre-
can degradation is part of a coordinated sequential 
(See figure on previous page.) 
Fig. 3 Metabolic activity and ECM turnover in pro‑inflammatory bovine cartilage explants. Bovine cartilage explants were pre‑cultured for 1 week 
with OSM + TNF‑α (5/10 ng/mL), and then cultured for further 5 weeks with weekly administration (48 h duration) of indicated compounds. 
Metabolic activity (a) was measured using AlamarBlue after 5 weeks of compound‑culturing. ProC2 (b), C2M (c), AGNx2 (d) and AGNx1 (e) (Nordic 
Bioscience) was measured in conditioned media collected at 0, 1, 2, 3, 4 and 5 weeks of compound‑culturing, and values were placebo‑corrected. 
All values are mean ± SEM of six replicate explants. One‑way ANOVA was used for multiple comparisons to the placebo group at each time point. 
To compare the biomarker responses following pro‑inflammatory and non‑inflammatory (Fig. 2) pre‑culturing, the iAUC of similar doses under each 
condition were calculated, and presented as mean ± SEM of six replicate explants (graph to the right). Unpaired t‑tests were used to compare the 
two conditions. Significance levels are indicated by asterisks; *P < 0.05, **P < 0.01, ***P < 0.001. All results are from one study (Study 2)
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process eventually leading towards cartilage regenera-
tion. As illustrated in Fig.  4, such a cartilage regenera-
tive process may hypothetically proceed as follows: 
resting chondrocytes residing in the cartilage ECM are 
stimulated by a pro-proliferative compound, like sprifer-
min, and start proliferating. However, expansion of the 
chondrocyte population is limited by the rigid ECM sur-
rounding the chondrocytes. Thus, chondrocytes induce 
matrix degradation to expand the lacunae and allow pro-
liferation, which is followed by ECM production, now 
by a greater chondrocyte population (Fig.  4). Although 
additional research is needed to confirm this observa-
tion, the slight increase in AGNx1 might suggest that 
matrix degradation is needed for expansion of lacunae, 
which may be needed to initiate the process of cell pro-
liferation and cartilage formation.
Another aspect of AGNx1 release during cartilage 
regeneration is the potential bioactivity of the aggrecan 
fragment. A 32-mer fragment of aggrecan was shown to 
have both anti-anabolic, pro-catabolic and pro-inflam-
matory effects on chondrocytes, synovial fibroblast and 
macrophages in  vitro [22]. This fragment contains the 
same C-terminal sequence  (NITEGE373) as detected in 
the AGNx1 ELISA, but whether NITEGE alone has bio-
active properties remains unknown. However, what is 
already known about the 32-mer fragment, clearly dem-
onstrates that tissue remodelling may generate bioactive 
fragments, which do not only affect the tissue of origin, 
but may be released to the joint cavity and affect other 
joint tissues as well.
Interestingly, the results suggest that sprifermin is less 
potent in inducing an anabolic response in articular car-
tilage following inflammatory conditions as compared to 
non-inflammatory conditions. When explants were cul-
tured with pro-inflammatory cytokines (OSM + TNF-α) 
prior to sprifermin treatment, little to no induction of 
type II collagen formation was observed, and the pat-
tern of ECM degradation biomarkers was changed. Other 
studies have further shown that continuous co-culturing 
with OSM + TNF-α throughout the compound-culturing 
period completely abolished sprifermin-induced type II 
collagen formation (unpublished data). In a clinical con-
text, this indicates that the cartilage regenerative effects 
of sprifermin may be influenced by the inflammatory sta-
tus of the joint cavity. Hence, sprifermin may be a more 
effective DMOAD for OA patients with a low degree of 
synovitis, i.e. patients with expected lower levels of pro-
inflammatory cytokines. Generally, such considerations 
of matching the right treatment with the right patient are 
highly important for succeeding in the development of 
novel OA therapies.
The present study was performed using full-depth 
articular cartilage explants to allow investigation of 
the cartilage tissue in its entirety. This model is limited 
to investigation of cartilage and do not account for the 
influence of other joint tissues or mechanical factors. The 
cartilage was of young bovine origin, hence is obviously 
more healthy than the cartilage of human OA patients, 
which is ultimately the target tissue of sprifermin. On 
the contrary, the human OA cartilage available would 
be from end-stage patients and may therefore already 
be too destroyed. Moreover, the large degree of patient-
to-patient variation makes it difficult to get a statistically 
valid output from human OA cartilage.
Conclusions
Sprifermin had an anabolic effect on articular cartilage, 
inducing cell proliferation, increased metabolic activity 
and formation of type II collagen. These chondrogenic 
effects seem to be accompanied by a sequential process 
Fig. 4 Sequential process of cartilage regeneration. Cartilage regeneration illustrated as a coordinated sequential process of chondrocyte prolifera‑
tion and matrix turnover. The process may be initiated by sprifermin signaling to the chondrocytes to start proliferating. However, the chondro‑
cytes are caged by the surrounding matrix, which preclude unlimited expansion. This may force the chondrocytes to initiate matrix degradation 
processes to expand the lacunae (get rid of their cage), and eventually we may see a larger population of chondrocytes that starts producing new 
matrix. Note that this figure illustrates a working hypothesis (and is hypothetical) as we do not know whether matrix degradation is required for 
regeneration of cartilage by pro‑proliferative compounds like sprifermin
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of ECM turnover, initiated by aggrecanase-mediated 
aggrecan degradation, then type II collagen formation 
and eventually aggrecan formation. No indication of 
increased MMP activity was observed. After pro-inflam-
matory pre-activation of the cartilage, sprifermin was 
unable to induce formation of type II collagen to the 
same extent as after non-inflammatory pre-culturing, 
and the general pattern of ECM turnover was changed.
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